Pharmacogenomic Analysis of Genetic Variability in Drug Metabolizing Enzymes-Implications for Personalized Medicine
DOI:
https://doi.org/10.63682/jns.v14i6.3261Keywords:
pharmacogenetics, cytochrome P450, UDP-glucuronosyltransferase, polymorphism, drug metabolismAbstract
Background: IIV is due in part to genetic polymorphisms of drug-metabolizing enzymes. This study aimed to compare variations in CYP2D6, CYP2C9, CYP3A4, and UGT1A1 enzymes and their activities in patients.
Methods: Genotyping for CYP2D6 (*1A/*2G/*3T), CYP2C9 (*1C/*2T/*3A), CYP3A4 (*1A/*2G), and UGT1A1 (*28T/*36A) polymorphisms in 500 participants. Genotype frequencies were obtained and checked for compatibility with Hardy-Weinberg equilibrium. Regression analysis evaluated the relationship between genotypes and enzyme activity for each enzyme.
Results: Allele frequencies which varied from 20-60% indicated that there was heterogeneity within the population. Analysis of genotype distribution revealed no deviation from Hardy-Weinberg equilibrium for any of the genotyped loci. The *1/wild-type alleles of CYP2D6, CYP2C9, and CYP3A4 had higher regression coefficients (0.45-0.55) of enzyme activity indicating that compared to variant alleles, the alleles were highly active. Comparing the two alleles for UGT1A1, *36A had a 60% higher activity versus *28T.
Conclusions: As observed, polymorphisms were statistically related to variations in enzyme activity among individuals for the analyzed drug-metabolizing enzymes
Downloads
Metrics
References
Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015 Feb 26;372(9):L8 793.
Evans WE, Relling MV. Application field 3: Moving towards individualized medicine with pharmacogenomics. Nature. 2004 May 27;429(6990):464-8.
Meyer UA. An overview of pharmacogenetics – the first five decades of therapeutic experience based on human genetic variability. Nat Rev Genet. 2004 Sep;5(9):669-76.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: lifestyle and its control on gene expression, enzymes, and molecular genetics consequences of genetic differences. Pharmacol Ther. 2013 Apr;138(1):103-41.
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. PMID: 19817501.
Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012 Feb;91(2):321-6.
Binkhorst L, Mathijssen RH, Jager A, van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev. 2015 Mar;41(3):289-99. doi: 10.1016/j.ctrv.2015.01.002. Epub 2015 Jan 14. PMID: 25618289.
Delion P, Labreuche J, Deplanque D, Cohen D, Duhamel A, Lallié C, Ravary M, Goeb JL, Medjkane F, Xavier J; Therapeutic Body Wrap Study group. Therapeutic body wraps (TBW) for treatment of severe injurious behaviour in children with autism spectrum disorder (ASD): A 3-month randomized controlled feasibility study. PLoS One. 2018 Jun 29;13(6):e0198726. doi: 10.1371/journal.pone.0198726. PMID: 29958284; PMCID: PMC6025870.
Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002 Apr;12(3):251-63. doi: 10.1097/00008571-200204000-00010. Erratum in: Pharmacogenetics 2002 Jun;12(4):343. PMID: 11927841.
Johnson JA, Cavallari LH. Pharmacogenetics and warfarin therapy. Trends Cardiovasc Med. 2015 Jan;25(1):33-8.
Zanger UM, Turpeinen M, Klein K, Schwab M. Interindividual differences in human cytochrome P450 2C9 activity are controlled by distinct genetic factors. Anal Bioanal Chem. 2008 Jun;392(6):1093-108.
Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): further developments and trends in relation to polymorphisms, mechanisms and clinical implications. Front Genet. 2013;4:24.
Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP- glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med. 1995 Dec 21;333(25) 1171- 5.
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15;22(8):1382-8. doi: 10.1200/JCO.2004.07.173. Epub 2004 Mar 8. PMID: 15007088.
Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015 Oct 15;526(7573):343-50.
McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):371-82. doi: 10.1517/17425255.2012.657626. Epub 2012 Jan 31. PMID: 22288606.
Sistonen, J., Fuselli, S., Palo, J. U., Chauhan, N., Padh, H., & Sajantila, A. (2012). Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009 Feb;19(2):170-9.
Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010 Jul 22;363(4):301-4. doi: 10.1056/NEJMp1006304.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007 Dec;9(12):819-25. doi: 10.1097/gim.0b013e31815bf9a3. PMID: 18091431; PMCID: PMC2743615.
Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetic variations for the different responses to drugs. Circulation. 2011 Apr 19;123(15):1661-70.
Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolising enzymes. Biomed Pap, Med Fac, Univ Palacky Olomouc, Czech Repub. 2010;154(2):103-16.
Nebert DW, Russell DW. The role of the cytochromes P450 in clinical setting. Lancet. 2002;360(9340):1155-62.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: their involvement in controlling gene expression, enzymatic activities, and effects of genetic differences. Pharmacol Ther. 2013;138(1):103-41.
Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: However, it is critical to note that the three processes of metabolism, expression, and disease are not mutually exclusive. Annu Rev Pharmacol Toxicol. 2000;40:581-616.
Hayes JD, Flanagan JU, & Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51-88.
Zanger UM, Turpeinen M, Klein K, Schwab M. Cytochrome P450 2C9 amino acid polymorphisms: enzymatic properties and prediction of inter-individual mall metabolism. Anal Bioanal Chem. 2008;392(6):1093-108.
Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy. Clin Pharmacol Ther. 2014;95(4):376-82.
Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, et al: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016;99(4):363-9.
Weinshilboum R. Genetic basis for drug action: inheritance and clinical pharmacology. N Engl J Med. 2003;348(6): 529-37.
Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy. Clin Pharmacol Ther. 2014;95(4):376-82.
Umamaheswaran G, Kumar DK, Adithan C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. Indian J Med Res. 2014 Jan;139(1):27-65. PMID: 24604039; PMCID: PMC3994740.
Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics Proteomics Bioinformatics. 2016 Oct;14(5):298-313. doi: 10.1016/j.gpb.2016.03.008. Epub 2016 Oct 8. Erratum in: Genomics Proteomics Bioinformatics. 2018 Apr 21;: PMID: 27729266; PMCID: PMC5093856.
Sharp CN, Linder MW, Valdes R Jr. Polypharmacy: a healthcare conundrum with a pharmacogenetic solution. Crit Rev Clin Lab Sci. 2019 Nov 2;57(3):161-180. doi: 10.1080/10408363.2019.1678568. PMID: 31680605; PMCID: PMC7195220.
Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST; Pharmacogenetics Research Network. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006 Nov 21;145(10):749-57. doi: 10.7326/0003-4819-145-10-200611210-00007. PMID: 17116919; PMCID: PMC5006954.
Zhang H, De T, Zhong Y, Perera MA. The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation? Clin Pharmacol Ther. 2019 Aug;106(2):338-349. doi: 10.1002/cpt.1491. PMID: 31038731; PMCID: PMC6663589.
Gershon ES, Alliey-Rodriguez N, Grennan K. Ethical and public policy challenges for pharmacogenomics. Dialogues Clin Neurosci. 2014 Dec;16(4):567-74. doi: 10.31887/DCNS.2014.16.4/egershon. PMID: 25733960; PMCID: PMC4336925.
Yang M, Kim JW. Principles of Genetic Counseling in the Era of Next-Generation Sequencing. Ann Lab Med. 2018 Jul;38(4):291-295. doi: 10.3343/alm.2018.38.4.291. PMID: 29611378; PMCID: PMC5895857.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
